Jim Bristol - ESSA Pharma Consultant
| EPIX Stock | USD 0.19 0.01 5.00% |
Executive
Jim Bristol is Consultant of ESSA Pharma
| Phone | 778 331 0962 |
| Web | https://www.essapharma.com |
ESSA Pharma Management Efficiency
The company has return on total asset (ROA) of (0.1525) % which means that it has lost $0.1525 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2125) %, meaning that it created substantial loss on money invested by shareholders. ESSA Pharma's management efficiency ratios could be used to measure how well ESSA Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| MiRa Huyghe | Spyre Therapeutics | N/A | |
| James Myers | Spyre Therapeutics | N/A | |
| Laura MD | Summit Therapeutics PLC | N/A | |
| Bhaskar Anand | Summit Therapeutics PLC | 47 | |
| Robert LaCaze | Summit Therapeutics PLC | N/A | |
| Andrew Dwyer | Summit Therapeutics PLC | 75 | |
| Eric McIntyre | Spyre Therapeutics | N/A | |
| Betty Chang | Summit Therapeutics PLC | N/A | |
| Melissa Cooper | Spyre Therapeutics | N/A | |
| Janet MBA | Spyre Therapeutics | N/A | |
| Justin LaFountaine | Spyre Therapeutics | N/A | |
| Abby Murphy | Summit Therapeutics PLC | N/A | |
| LLM JD | Spyre Therapeutics | 42 | |
| Scott Burrows | Spyre Therapeutics | 48 | |
| Andrew Spencer | Spyre Therapeutics | N/A | |
| Deanna MD | Spyre Therapeutics | N/A | |
| Fong Clow | Summit Therapeutics PLC | N/A | |
| John Raymond | Spero Therapeutics | N/A | |
| Sheila Finan | Spero Therapeutics | N/A | |
| Paul JD | Spyre Therapeutics | 59 | |
| Dave Gancarz | Summit Therapeutics PLC | N/A | |
Management Performance
| Return On Equity | -0.21 | ||||
| Return On Asset | -0.15 |
ESSA Pharma Leadership Team
Elected by the shareholders, the ESSA Pharma's board of directors comprises two types of representatives: ESSA Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ESSA. The board's role is to monitor ESSA Pharma's management team and ensure that shareholders' interests are well served. ESSA Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ESSA Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Erin Rudsinski, Executive | ||
| Jim Bristol, Consultant | ||
| CMA CPA, Chief Officer | ||
| Roger Ulrich, Consultant | ||
| Kim Hewitt, Consultant | ||
| Neil Thapar, Executive | ||
| Alessandra MD, Chief Officer | ||
| Erica Osbourne, Executive | ||
| Steve Pondell, Executive | ||
| Stephen MD, Consultant | ||
| Terry Schuenemeyer, Executive | ||
| MS MBA, Executive COO | ||
| Nkengyal Barber, Executive | ||
| Chandtip Chandhasin, Executive | ||
| Loleta Harris, Executive | ||
| David MD, CEO and President and Director | ||
| Kally Singh, Consultant |
ESSA Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ESSA Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.21 | ||||
| Return On Asset | -0.15 | ||||
| Current Valuation | (100.02 M) | ||||
| Shares Outstanding | 47.31 M | ||||
| Shares Owned By Insiders | 5.64 % | ||||
| Shares Owned By Institutions | 74.15 % | ||||
| Number Of Shares Shorted | 3.66 M | ||||
| Price To Earning | (1.12) X | ||||
| Price To Book | 0.09 X | ||||
| EBITDA | (28.45 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for ESSA Stock Analysis
When running ESSA Pharma's price analysis, check to measure ESSA Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ESSA Pharma is operating at the current time. Most of ESSA Pharma's value examination focuses on studying past and present price action to predict the probability of ESSA Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ESSA Pharma's price. Additionally, you may evaluate how the addition of ESSA Pharma to your portfolios can decrease your overall portfolio volatility.